Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
- 13 December 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (2) , 784-803
Abstract
Factor XIa inhibitors are promising novel anticoagulants which show excellent efficacy in preclinical thrombosis models with minimal effects on hemostasis. The discovery of potent and selective FXIa inhibitors which are also orally bioavailable has been a challenge. Here, we describe optimization of the imidazole-based macrocyclic series and our initial progress towards meeting this challenge. A two-pronged strategy, which focused on replacement of the imidazole scaffold and the design of new P1 groups, led to the discovery of potent, orally bioavailable pyridine-based macrocyclic FXIa inhibitors. Moreover, pyridine-based macrocycle 19, possessing the phenylimidazole carboxamide P1, exhibited excellent selectivity against relevant blood coagulation enzymes and displayed antithrombotic efficacy in a rabbit thrombosis model.Keywords
This publication has 52 references indexed in Scilit:
- Antithrombotic AgentsCirculation Research, 2019
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2018
- Factor XIa Inhibitors as New AnticoagulantsJournal of Medicinal Chemistry, 2018
- New Oral Anticoagulants in Nonvalvular Atrial FibrillationClinical Cardiology, 2016
- Factor XI Deficiency or Hemophilia C2014
- Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trialsBMJ, 2012
- Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosisThrombosis and Haemostasis, 2011
- Reduced incidence of ischemic stroke in patients with severe factor XI deficiencyBlood, 2008
- Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XIIBlood, 2006
- Inherited factor XI deficiency confers no protection against acute myocardial infarctionJournal of Thrombosis and Haemostasis, 2003